AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01620723 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Health professionals offer the usual care for the breastfeeding mother
Study NCT02229383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: 2 mg weekly suspension injection
Study NCT02229383 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Exenatide matching placebo
Description: Once weekly Placebo injection
Study NCT04057365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is believed to work by attaching to and inhibiting a specific protein in the cancer that controls parts of the immune system (the system in the body that fights off infections and diseases) by shutting down certain immune responses. The investigators believe that nivolumab will inhibit the protein, thus allowing the immune cells to recognize and destroy cancer cells.
Study NCT02770248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brinzolamide 1%/brimonidine 0.2% tartrate ophthalmic suspension
Study NCT02770248 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vehicle
Description: Inactive ingredients used as a placebo for masking purposes
Study NCT01322919 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Supracor
Description: All patients will undergo LASIK treatment on their non-dominant eye with a new laser software algorithm designed to treat both the distance and near vision components.~The developed software algorithm uses the subjective refraction of the eye to create a treatment for the distance vision correction. This part of the treatment does not show any difference to a regular LASIK treatment for ametropic cases.~In addition to the treatment for the distance vision a central ablation component will be added to address the near vision.
Study NCT02698241 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Diagnostic & Medication Management
Description: Single Arm Study. Subjects will be managed using integrated diagnostics.
Study NCT03809299 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Ad libitum meal timing
Description: Research participants will eat meals provided by the study throughout the day, ad libitum
Study NCT03809299 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Twice a day meals
Description: Research participants will eat meals provided by the study at two intervals during the day, and fast in between.
Study NCT03317535 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: General anesthesia
Description: Patients will be injected with propofol, remifentanil and muscular relaxant with controlled ventilation.
Study NCT03317535 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Local anesthesia/concious sedation
Description: Patients will be injected with propofol and remifentanil.
Study NCT03317535 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Spontaneous breath
Description: Patients will be kept spontaneous breath.
Study NCT03317535 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Controlled ventilation
Description: Patient will be kept with controlled ventilation.
Study NCT02639429 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal Misoprostol
Study NCT02639429 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Foley Balloon + Vaginal Misoprostol
Study NCT01673113 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zeltiq CoolSculpting device
Description: This is an FDA approved cooling device used for non-invasive and selective reduction of fat around the flanks, an area commonly referred to as the love handles.
Study NCT04479540 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Angiography scanner
Description: systematic thoracic angiography scanner to diagnose pulmonary embolism and additional blood sample (hemostasis exploration)
Study NCT01975467 — intervention group
Intervention type: DEVICE
Intervention: CRx
Description: The CRx is used to treat mid-shaft, with or without comminution clavicle fractures.
Study NCT03332134 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intimate Partner Violence (IPV) Prevention Intervention
Description: The IPV intervention consists of six sessions. Each session will cover one of 6 major modules to enhance transformation of motivation: 1) You, Me, and Us: Spending Meaningful Time Together, 2) I'm a Champion: I Can't Be Broken and I don't Accept Defeat! 3) Building Communication and conflict management strategies, and 4) Empowerment of the Couple: Planning Ahead, 5) Sexual communication and the sexual relationships, and 6) A Lens into Domestic Violence. The sessions will be audio-recorded and include a combination of didactics, interactive discussions, media use, and role play. The expected durations of session 1, 2-6, and the 3-month follow-up are 120 minutes, and 60-90 minutes, respectively.
Study NCT01144182 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Comprehensive quality improvement program (QIP)
Description: Comprehensive quality improvement program (QIP) that intervenes on patient, provider and system levels. The QIP will consist of 3 monthly phone calls to promote diet and medication adherence using the transtheoretical model as a behavioral framework and checklists to facilitate patients' self-monitoring of their diet, physical activity, weight and medication taking. Further, providers during the posttest phase will use checklists for inpatient and outpatient care of HF patients.
Study NCT06123585 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Invisalign® SmileView™
Description: Pretreatment smiles were captured using the Invisalign® SmileView™ to simulate their new smiles before treatment was started.
Study NCT06123585 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Invisalign aligners
Description: Patients were then treated using upper and lower Invisalign aligners with average treatment time of 12±3 months.
Study NCT03360396 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endobronchial Coils
Description: Endobronchial Coil implants
Study NCT02323802 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: educational group intervention
Study NCT02323802 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: prescriptive diet
Study NCT02266849 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Loperamide
Description: 12 mg Loperamide each day for three days
Study NCT02266849 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 6 tablets daily for three days
Study NCT02270749 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxocobalamin
Description: patients are treated for 6 months with hydroxocobalamin. Patients will be treated with once a dose of 2000ug, after that treatment will be continued with a dose of 1000ug per 2 months. At timepoint 0, 2, 4 and 6 months after treatment vitamin B12 will be measured. At timepoint 0 and 6 also homocystein and methylmalonic acid will be measured.
Study NCT02270749 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FitForMe vitamin B12
Description: patients are treated for 6 months with a daily dose of 1000ug vitamin B12 tablets. At timepoint 0, 2, 4 and 6 months after treatment vitamin B12 will be measured. At timepoint 0 and 6 also homocystein and methylmalonic acid will be measured.
Study NCT02629250 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: SV maximization
Description: When SpO2 ≥92%, mean arterial pressure (MAP) 65-100 mmHg, HR \<100 bpm, Hb >8mg/dL and temperature ≥36℃, the patients will receive a 250 ml Ringer's lactate solution in 5 min as a fluid challenge for stroke volume (SV) maximization. The fluid challenge will repeat until the SV failed to increase by a factor of 10%. A reassessment on the SV maximization will be taken every 30 minutes and to restart algorithm when increased SV >10% or blood loss >250ml. Blood transfusions will be used to maintain a hemoglobin concentration over 8mg/dL.
Study NCT02629250 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: supernormal DO2
Description: Goal directed fluid therapy is administrated as group SV maximization. Then DO2I will be assessed. If at this stage the DO2I can not be greater than 600 mL/m2 (supernormal oxygen delivery goal), then dobutamine will be started at a dose of 2.5 μg/kg/min and increased by the same increment every 20 minutes until the described target is reached or until a maximal dose of 20 μg/kg/min is given. Dobutamine is decreased in dose or discontinued if the heart rate is above 100 beats per minute or shows signs of cardiac ischemia.
Study NCT02284347 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electromagnetic Sinus Dilation System (NuVent™)
Description: NuVent navigation-guided balloon system may be used to locate and move tissue, bone or cartilaginous tissue obstructing the drainage pathways of the frontal, maxillary, and sphenoid sinuses that is scarred, granulated or previously surgically-altered to facilitate dilation of the sinus ostia.
Study NCT00759278 — intervention group
Intervention type: PROCEDURE
Intervention: ultrasound evaluation in pregnancy
Description: Subjects enrolled will have a series of ultrasound evaluations to assess parameters in the study. Ultrasound is a non-invasive technique for creating images that does not use radiation and is routine in obstetrical practice
Study NCT01951287 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute beverage (water) consumption
Description: Acute beverage consumption includes water.
Study NCT01951287 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute beverage (Black Coffee) consumption
Description: Acute beverage consumption includes black coffee.
Study NCT01951287 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute beverage (Orange Juice) consumption
Description: Acute beverage consumption includes Orange Juice..
Study NCT01951287 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute beverage (Whole Milk) consumption
Description: Acute beverage consumption includes whole milk
Study NCT04057365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DKN-01
Description: DKN-01 is believed to work by attaching to and inhibiting (stopping) a specific pathway in the cells that is responsible for processes such as cell growth
Study NCT02351180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone
Description: Inhaled steroid that may decrease airway inflammation and the risk of chronic rejection
Study NCT02351180 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will serve as a control treatment
Study NCT00603356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OSI-930 and erlotinib
Description: OSI-930 administered daily in combination with Erlotinib at increasing doses until disease progression or unacceptable toxicity
Study NCT02930590 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alternating low pressure mattress with air loss function
Description: IsoAir, Stryker, USA
Study NCT01951287 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute beverage (2% Milk) consumption
Description: Acute beverage consumption includes 2% milk
Study NCT01951287 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute beverage (Skim Milk) consumption
Description: Acute beverage consumption includes skim milk
Study NCT02710591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rimeporide
Description: Cohort 1:~50 mg TID in patients with a body weight ≤ 30kg at Baseline and 75 mg TID in patients with a body weight > 30kg at Baseline~Cohort 2:~100mg TID in patients with a body weight ≤ 30kg at baseline and 150 mg TID in patients with a body weight > 30kg at Baseline~Cohort 3:~150 mg TID in patients with a body weight ≤ 30kg at baseline and 200 mg TID in patients with a body weight > 30kg at Baseline~Cohort 4:~200 mg TID in patients with a body weight ≤ 30kg at Baseline and 300 mg TID mg TID in patients with a body weight > 30kg at Baseline
Study NCT02849236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine (PECS bloc)
Description: Ropivacaine 3.75mg/mL~Injection of a local anesthetic between pectoral major and pectoral minor muscles
Study NCT03833674 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Respiratory Strength Training Block
Description: Respiratory strength training using a hand-held device that resists inspiration or expiration.
Study NCT03833674 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AIH + Strength Training Block
Description: AIH followed by respiratory strength training.
Study NCT04111887 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group-based therapy
Description: College students with depressive symptoms will be randomized to one of three conditions: 1) a cognitive behavioral prevention intervention, 2) a cognitive behavioral prevention intervention with counter-attitudinal elements or 3) an educational brochure control. We will test if the additional of counter attitudinal elements produces intervention effects when delivered to participants with sub threshold depressive symptoms.
Study NCT04111887 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Group-based therapy
Description: College students with depressive symptoms will be randomized to one of three conditions: 1) a cognitive behavioral prevention intervention, 2) a cognitive behavioral prevention intervention with counter-attitudinal elements or 3) an educational brochure control. We will test if the additional of counter attitudinal elements produces intervention effects when delivered to participants with sub threshold depressive symptoms.
Study NCT02849236 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 20 mL saline 0.9%
Study NCT02930590 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gel mattress
Description: IsoGel, Stryker, USA
Study NCT01474915 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aprepitant
Description: Subject will receive 40 mg of Aprepitant versus placebo PO before anesthesia induction
Study NCT02930590 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Basic foam
Description: Standard hospital mattress
Study NCT01071967 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community-based nurse care management
Description: The community-based nurse care management program developed by Health Quality Partners uses nurses working in the community to provide the following integrated set of services to older adults with chronic illness over the long term in order to prevent avoidable complications of their diseases and aging; geriatric assessment, care coordination, health education, self-management coaching, weight management, physical activity, gait and balance training, medication adherence, care transition support, ongoing monitoring and symptom detection, collaborative problem solving with patients, families and health care providers.
Study NCT03503630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COMPOUND 2055269
Description: COMPOUND 2055269 to be given every 2 weeks with chemotherapy for 6 cycles
Study NCT03503630 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Radiotherapy 25 Gy to be given on Days 1-5
Study NCT03503630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX
Description: Given every 2 weeks for 6 cycles
Study NCT03503630 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total Mesorectal Excision
Description: Surgery to be done 2-3 weeks after last cycle of chemotherapy and COMPOUND 2055269
Study NCT04481906 — intervention group
Intervention type: PROCEDURE
Intervention: Vaginal mesh for female cystocele
Description: Vaginal mesh procedures (e.g. Perigee) were susgested for women with POP-Q stage III or more cystocele
Study NCT02619266 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture is the practice of inserting thin needles into specific points to improve health and well-being.
Study NCT02619266 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sham Acupuncture
Description: Sham acupuncture is used as a control in scientific studies that test the efficacy of acupuncture in the treatment of various illness or disorders.
Study NCT02619266 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sham Acupuncture
Description: Sham acupuncture is used as a control in scientific studies that test the efficacy of acupuncture in the treatment of various illness or disorders.
Study NCT02619266 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Megestrol Acetate
Description: Megestrol Acetate 160mg tablet
Study NCT02619266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo(Megestrol Acetate)
Description: Starch pill manufactured to mimic Megestrol Acetate 160mg tablet
Study NCT02619266 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo(Megestrol Acetate)
Description: Starch pill manufactured to mimic Megestrol Acetate 160mg tablet
Study NCT03505099 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: onasemnogene abeparvovec-xioi
Description: A non-replicating recombinant AAV9 containing the complimentary deoxyribonucleic acid (cDNA) of the human SMN gene under the control of the cytomegalovirus (CMV) enhancer/chicken-β-actin-hybrid promoter (CB). The AAV inverted terminal repeat (ITR) has been modified to promote intramolecular annealing of the transgene, thus forming a double-stranded transgene ready for transcription.
Study NCT03854006 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cryoballoon pulmonary vein isolation
Description: During cryoballoon pulmonary vein isolation, under local anaesthesia, diagnostic catheters are placed in the coronary sinus. The cryoballoon is advanced to the left atrium via a steerable sheath after single transseptal puncture and inflated at the PV(pulmonary vein) ostia. A spiral mapping catheter is advanced through the balloon inner lumen and positioned in the PV at the closest achievable proximity to the cryoballoon in order to record real-time PV potentials during PV isolation. During PV isolation the potentials from the PV are recorded. The TTI is defined as the time of the last recording of a PV potential before sustained isolation. Isolation of all PVs is reassessed at the end of the procedure by documentation of entrance- and exit-block.
Study NCT00829751 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PureVision lenses soaked in ReNu Multiplus
Description: Purevision silicone hydrogel lenses
Study NCT00829751 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PureVision lenses soaked in OptiFree RePlenish
Description: Purevision silicone hydrogel lenses soaked in OptiFree RePlenish
Study NCT01979913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saflutan® 15 microgram/ml Augentropfen im Einzeldosisbehältnis
Study NCT02160106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEW-7197
Description: Single daily doses by oral administration on Days 1, 2, 3, 4, 5, Days 8, 9, 10, 11, 12, Days 15, 16, 17, 18, 19 and Days 22, 23, 24, 25, 26 of each 28 day cycle. Starting dose is 30 mg, with escalation to 60 mg, and subsequent dose escalation using a modified Fibonacci algorithm.
Study NCT02341924 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Portfolio of functional foods
Study NCT02341924 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control foods
Study NCT01751724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine citrate
Description: Enrolled subjects will be randomized to receive a study drug consisting of either blinded Caffeine citrate.~Randomization and study drug preparation will be done by the NICU pharmacy. Investigators and clinicians will be blinded to the assigned drug.~After randomization, an initial loading dose of 20 mg/Kg of study drug will be followed by a 5 mg/Kg/day maintenance dose. The assigned study drug will be administered intravenous or orally as determined by the clinical team.~Infants will continue to receive the study drug until 12 hours prior to the first elective extubation.
Study NCT01751724 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Enrolled subjects will be randomized to receive a study drug consisting of blinded Placebo (equivalent volume of normal saline).~Randomization and study drug preparation will be done by the NICU pharmacy. Investigators and clinicians will be blinded to the assigned drug.~After randomization, an initial loading dose of 20 mg/Kg of study drug will be followed by a 5 mg/Kg/day maintenance dose. The assigned study drug will be administered intravenous or orally as determined by the clinical team.~Infants will continue to receive the study drug until 12 hours prior to the first elective extubation.
Study NCT02584153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fibrin Sealant
Description: TISSEEL® fibrin sealant (Baxter Biosurgery, Deerfield, IL)
Study NCT02584153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silver Microparticles
Description: Product Code: AG-M-04M-P.200M (American Elements, Los Angeles, CA)
Study NCT01705249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1.0 mg estradiol / 0.5 mg norethisterone acetate (NETA)
Description: After a screening period of 12 weeks (three lunar months) in which the subjects still are on Trisekvens® followed by a treatment period of 24 weeks (six lunar months) in which the subjects are treated with Activelle®.
Study NCT03942042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixekizumab
Description: Administered SC
Study NCT00156117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: asenapine
Description: 5 mg BID or 10mg BID